Damora Therapeutics, Inc.

NASDAQ:DMRA

Biotechnology

Healthcare
$22.98 +0.34%

+$0.07 today

Market cap
$1.42B
Beta
1.48
P/E (TTM)
-0.1
EPS (TTM)
-$177.15
52W Low $2.45High $38.33

Volume 0.58M

Average 0.33M

DMRA Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Damora Therapeutics, Inc.NASDAQ: DMRA

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables of $0 in Q1 FY2026

Q1 FY2026 accounts receivables was $0. Trailing-twelve-month accounts receivables was $0.

Context

  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2024
$0— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Accounts Receivables vs competitors

How DMRA compares with its peers on the latest reported figures

  • DMRA's LTM Jun 2024 accounts receivables of $0 is the 7th largest of the 9 companies compared; the peer median is $5.12M.
DMRA Competitors Peer median
Accounts Receivables for DMRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$282.32M +167.9%+81.5%4.9%
GMABGenmab A/SLTM Jun 2026$189.32M —-57.2%4.6%
KROSKeros Therapeutics, Inc.LTM Mar 2026$14.64M +185.8%—44.1%
GERNGeron CorporationLTM Mar 2026$9.92M -69.2%-35.1%5.1%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$8.4M -40.2%-25.8%2.8%
QUREuniQure N.V.LTM Mar 2026$1.84M -135.4%-44.0%10.2%
DMRADamora Therapeutics, Inc.LTM Jun 2024$0 ———
IRONDisc Medicine, Inc.LTM Sep 2026$0 ———
COAGHemab Therapeutics Holdings, Inc. Common StockFY2025$0 ———
Peer median (excluding DMRA) $5.12M-40.2%-35.1%5.0%

Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(51.75M)(61.62M)(38.35M)(21.44M)(209.84M)
Depreciation & Amortization441K490K830K181K34K
Deferred Income Tax00000
Stock-Based Compensation0000998K
Change in Working Capital(6.62M)11.94M(4.37M)(2.67M)18.36M
Accounts Receivables00000
Inventory00000
Accounts Payables(1.32M)1.82M(1.65M)(1.33M)17.27M
Other Working Capital(5.3M)10.12M(2.72M)(1.34M)1.09M
Other Non-Cash Items5.63M6.27M4.98M5.3M183.72M
Operating Cash Flow(52.31M)(42.93M)(36.91M)(18.62M)(6.73M)
Capital Expenditures(223K)(196K)000
Acquisitions (Net)0083K0(17.37M)
Purchases of Investments(84.21M)(44.87M)(25.94M)00
Sales of Investments36.38M57.45M48.18M11.65M0
Other Investing Activities00000
Investing Cash Flow(48.05M)12.38M22.33M11.65M(17.37M)
Debt Repayment00000
Common Stock Issued0507K2.88M00
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities000033K
Financing Cash Flow0507K2.88M0266.84M
Effect of Forex Changes(663K)264K384K(317K)705K
Net Change in Cash(101.02M)(29.78M)(11.32M)(7.29M)243.45M
Free Cash Flow(52.53M)(43.13M)(36.91M)(18.62M)(6.73M)

Damora Therapeutics, Inc.

NASDAQ:DMRA

Intrinsic Alpha fair value

Locked

Current Price

$22.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.